TESARO,Inc. (NASDAQ:TSRO) Files An 8-K Regulation FD Disclosure


TESARO,Inc. (NASDAQ:TSRO) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On March14, 2018, TESARO,Inc. (the “Company”) is presenting at Barclay’s Global Healthcare Conference at 2:35 p.m.Eastern. A webcast of the Company’s presentation and the accompanying slides can be found on the investor relations website at http://ir.tesarobio.com/events-and-presentations. The Company’s presentation contains the same guidance relating to expected 2018 revenues for ZEJULA disclosed by the Company in its earnings release included as Exhibit99.1 to the Company’s Current Report on Form8-K furnished with the Securities and Exchange Commission on February27, 2018 and in the Company’s slides that accompanied its year-end earnings presentation, which can also be found on the investor relations website.


TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform. It offers VARUBI (rolapitant), which is an oral substance P/neurokinin 1 (NK-1) receptor antagonist for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. It is developing IV formulation of rolapitant, which has completed various Phase 1 clinical trials. Its niraparib is an orally active and poly (ADP-ribose) polymerase (PARP) inhibitor. Its immuno-oncology platform has immuno-oncology programs, which include TSR-022 and TSR-042.

An ad to help with our costs